Microcirculatory disorders and role of serotonin in formation of heart failure with preserved ejection fraction
Abstract
Over the past decades, has been recorded a steady increase of patients with heart failure with preserved ejection fraction (HFpEF), which is a complex clinical syndrome and includes a combination of several concomitant diseases. Based on the results of some studies, it is suggested that at the base of HFpEF there are alterations of the arteriolar-capillary bed. In our research, we’ve studied the microcirculation disorders in patients with HFpEF and the concentration of serotonin in the blood plasma as a possible biomarker for assessing of systemic microcirculation.
About the Authors
M. V. Kurkina
Russian Medical Academy of Continuing Vocational Education
Russian Federation
Russian Federation
A. P. Roytman
Russian Medical Academy of Continuing Vocational Education
Russian Federation
Russian Federation
N. G. Rakova
Russian Medical Academy of Continuing Vocational Education
Russian Federation
Russian Federation
A. G. Avtandilov
Russian Medical Academy of Continuing Vocational Education
Russian Federation
Russian Federation
References
1. Barry A. Borlaug, Redfield M. М. et al. Diastolic and Systolic Heart Failure are Distinct Phenotypes of the Heart Failure Syndrome // Circulation.- 2011.- Vol. 123, № 18.- Р. 2006-14.
2. Zile M. R., Gaasch W. H. et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure // Circulation.- 2001.- Vol. 104, № 7.- P. 779-82.
3. Narang N., Medvedofsky D., Kathryn D. et al. Microvascular dysfunction and cardiac fibrosis in heart failure with preserved ejection fraction: a case report // Heart Failure. - 2017.- Vol. 4, № 4.- Р. 645-48.
4. Crea F., Noel Bairey Merz С. et al. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift // European Heart Journal.- 2017.- Vol. 38, № 7.- Р. 473-77.
5. Kitzman D. W., Nicklas B. et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction // Am J Physiol Heart Circ. Physiol.- 2014.- Vol. 306, № 9.- Р. 1364-70.
6. Mohammed S. F., Hussain S., Mirzoyev S. A., et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction // Circulation.- 2015.- Vol. 131, № 6.- Р. 550-59.
7. Kitzman D. W., Upadhya B. et al. What the dead can teach the living: the systemic nature of heart failure with preserved ejection fraction // Circulation.- 2015.- Vol.131, № 6.- Р. 522-24.
8. May A. E., Seizer P., Gawaz M. Platelets: Inflammatory firebugs of vascular walls // Arterioscler. Thromb Vasc. Biol. - 2008.- Vol. 28, № 3.- Р. 5-10.
9. Natalia Lopez-Andres, Patrick Rossignol et al. Association of galectin-3 and fibrosis markers
10. with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial // European Journal of Heart Failure.-2012.- Vol. 14, № 1 - Р.74-81.
11. Odaka Y., Takahashi J.et al. Plasma concentration of serotonin is a novel biomarker for coronary microvascular dysfunction in patients with suspected angina and unobstructive coronary arteries // European Heart Journal.- 2017.- Vol. 38, № 7.- Р. 489-96.
12. Nagatomo T., Rashid M. et al. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system // Pharmacolody and therapeutics.- 2014.- Vol. 104; Р. 59-81.
13. Marzak H, Ayme-Dietrich E, Lawson R, Mokni W, Combe R, Becker J, et al. Old spontaneously hypertensive rats gather together typical features of human chronic left-ventricular dysfunction with preserved ejection fraction // J Hypertens. - 2014. - Vol. 32, № 11.- Р. 1307-16.
14. Ahmed M. Selim, Nitasha Sarswat, Losif Kelesidis et al. Plasma serotonin in heart failure: possible marker and potential treatment target // Heart lung and circulation.- 2017.- Vol.26, № 5.- Р.442-9.
15. Ganau A., Devereux R. B., Roman M. J. et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension // J. Am. Coll. Cardiol.- 1992.- Vol.19.- P. 1550-58.
16. Gaasch W. H., et al. Left ventricularstructural remodeling in health and disease: with special emphasis on volume, mass, and geometry // J Am CollCardiol.- 2011.- Vol. 58, № 17.- Р.1733-40.
17. Свищенко Е. П., Матова Е. А., Мищенко Л. А. Диастолическая дисфункция левого желудочка у больных гипертонической болезнью: возможности коррекции с помощью валсартана // Артериальная гипертензия. - 2012. № 2 (22).- С. 39-46.
18. Иванов С. В., Рябиков А. Н., Малютина С. К. Жесткость сосудистой стенки и отражение пульсовой волны в связи с артериальной гипертензией // Бюллетень со РАМН. - 2008. № 3 (131). - С. 9-12.
19. Kim H, Jun D. W. et al. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction // Echocardiography.- 2008.- Vol.25, № 9.- Р. 961-7.
20. Birkeland J. A., Sjaasted I., Qvigstad E., Moberg E. R., Krobert K. A. et al. Effects of treatment with a 5- HT4 receptor antagonist in heart failure // Br J Pharmrcol.-2007.- Vol. 150 № 2.- Р. 143-52.
Review
For citations:
Kurkina M.V., Roytman A.P., Rakova N.G., Avtandilov A.G. Microcirculatory disorders and role of serotonin in formation of heart failure with preserved ejection fraction. Medical alphabet. 2018;3(26):47-51. (In Russ.)
Views:
267
Email this article 